Skip to main content
See every side of every news story
Published loading...Updated

J&J to Spin Off Orthopaedics Unit After Strong Q3 Results, Stock Falls 1%

Johnson & Johnson will create a standalone orthopedics company generating $9.2 billion in sales to focus on higher-growth, higher-margin drug and device markets, CFO said.

  • Johnson & Johnson on Tuesday raised its 2025 sales forecast by $300 million and said it will spin off its orthopedics unit into standalone DePuy Synthes within 18 to 24 months.
  • J&J says the split will give its drug and device operations more breathing room amid pressure from President Donald Trump to lower U.S. drug prices after recently spinning off Kenvue.
  • J&J reported stronger earnings and lifted its product revenue range to $93.5 billion–$93.9 billion, about $300 million higher after third-quarter revenue beat estimates at $24 billion.
  • Investors digested both the guidance raise and the planned leadership for the new company as shares rose about 2% in premarket trading but fell later, with Namal Nawana leading DePuy Synthes.
  • The move positions each company to sharpen focus, with J&J increasing U.S. investment, including a $15 billion pledge and a $2 billion Holly Springs project creating roughly 120 jobs.
Insights by Ground AI

29 Articles

Associated Press NewsAssociated Press News
+5 Reposted by 5 other sources
Lean Left

J&J lays out plan to splinter orthopedics business into separate company

Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 47% of the sources are Center
47% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

medtechdive.com broke the news in on Tuesday, October 14, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal